Pfizer announced that it has started a study of comparison between the original covid-19 vaccine and its booster shots in order to tweak it to curtail the omicron variant.
Pfizer and partner BioNtech announced this joint study on Tuesday.
The company also announced that it will be updating its shots in order to match the highly contagious omicron variant as the globally verified health authorities have announced that a change is mandatory to eradicate the world from the harrowing shadows of the coronavirus pandemic.
It has been noted that omicron spreads swiftly among the vaccinated individuals – which was not common among the previous variants. This showcased that the change is much needed.
The original vaccines offer high protection against severe illness and death and their boosters are also strengthening the protection layer by improving to avoid coronavirus infection.
“We recognize the need to be prepared in the event this protection wanes over time and to potentially help address omicron and new variants in the future,” Kathrin Jansen, Pfizer’s vaccine research chief, said in a statement.
The CEO of Pfizer announced that the new batch of vaccines that would be effective on the omicron dose will be ready as early as March, the company did call it an “at risk” manufacturing meaning that they might not be available for the public immediately.
Pfizer is planning to produce as many as 4 billion vaccine shots in the year 2022. The number of vaccine shots might change if the omicron-adapted shots are needed or are announced to be manufactured.
This new study will, later on, be converted into testing which will enable the tweaking of the already available vaccine shot in the market by Pfizer.
Pfizer and other vaccine manufacturers are already planning to conduct testing experimenting for doses that were effective on previous strains as well as new tweaked vaccine shots in order to work against the contagious omicron strain.
